Combined Synopsis/SolicitationPosted Sep 16, 2026·Responses due Sep 21, 2026

Promega Assay Reagents to Support Complement-ARIE Mechanistic Toxicology Research

National Institutes of Health · NATIONAL INSTITUTES OF HEALTH OLAO

Stage
Open solicitation
NAICS
325413
Value
Not stated
Solicitation
75N98026Q01226
Set-aside
No Set aside used
PSC
6550
Place
Durham, NC, USA
Contact
Jordan Neal (jordan.neal@nih.gov)
Loading your pipeline and notes…
CSV Email

Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.

Where this opportunity stands

Every notice posted under solicitation 75N98026Q01226 in this department, oldest first.

Early notice
None posted
Solicitation
  • Sep 16, 2026 · this notice
    Combined Synopsis/Solicitation
Award
Not yet. Typical award: Oct 2, 2026 to Dec 8, 2026, middle of the range Oct 14, 2026.
Measured from 139 past solicitations at National Institutes of Health that later posted an award (middle half of cases, counted from Sep 16, 2026).

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

  • Decide bid or no bid before the response deadline.
  • Look at the past winners for likely competitors and teaming partners.
  • Follow the opportunity to hear about amendments and the award.

What the notice says

1.0 DESCRIPTION This is a combined synopsis/solicitation for commercial products prepared in accordance with RFO FAR Part 12. This announcement constitutes the only solicitation. Offers are being requested, and a separate written solicitation will not be issued. Solicitation No. 75N98026Q01226 is issued as a Request for Quotation (RFQ) for Promega assay reagents to support Complement-ARIE mechanistic toxicology research. The Government intends to award a purchase order on a sole-source basis to Promega Corporation based on the Government's determination that Promega Corporation is the only sou… (show all)

rce identified as capable of satisfying the Government's requirements. However, all responsible sources may submit a quotation that demonstrates their ability to satisfy the complete requirements identified in this RFQ and the attached requirements document. All timely quotations will be considered by the Government. This RFQ is being posted to the Governmentwide Point of Entry (GPE) in accordance with RFO FAR 5.201. This acquisition will be conducted in accordance with RFO FAR Part 12 � Acquisition of Commercial Products and Commercial Services, using the simplified procedures at RFO FAR 12.201-1. The Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS), intends to procure, on a sole source basis, Promega assay reagents from the manufacturer, Promega Corporation, 2800 Woods Hollow Road, Madison, Wisconsin 53711. The Promega assay reagents are required to support Complement-ARIE research conducted by the National Center for Advancing Translational Sciences (NCATS) and NIEHS through the Mechanistic Toxicology Branch (MTB) within the Division of Translational Toxicology (DTT). The reagents will be used to assess cell viability, liver injury, liver function, oxidative stress, antioxidant responses, and cellular bioenergetics in human three-dimensional microphysiological systems and will complement cell painting and omics endpoints. Continued use of the specified assay reagents is necessary to support the established experimental approach, maintain consistency and comparability of research results, and provide the required sensitivity for evaluating toxicity responses in small three-dimensional microtissue models. Due to the specialized nature of the Complement-ARIE research and the Government�s requirement for the specific combination of assay reagents, luminescence/chemiluminescence-based detection, toxicological endpoints, and compatibility with the established experimental approach, the Government intends to procure these supplies on a sole-source basis from Promega Corporation. Promega Corporation manufactures the assay reagents identified in the Government�s requirement and, based on the market research conducted, is the only source identified that can satisfy the Government�s requirements. The Government has determined that these requirements are necessary to support the established research methodology, maintain comparability and reproducibility of results, and enable integration of the assay results with existing cell painting and omics-based analyses. The contractor shall provide the Promega assay reagents identified in the Government�s requirement and associated quotation. The reagents shall support measurement of cell viability, liver injury, liver function, oxidative stress, antioxidant responses, and cellular bioenergetics in human three-dimensional microphysiological systems. The contractor shall deliver the required supplies to NIEHS in Rall Building 101, laboratories E144-146, located at 111 T.W. Alexander Drive, Research Triangle Park, North Carolina 27709. Acceptance will be demonstrated by successful delivery and the successful performance of the specified assays within the NIEHS laboratory. There is no travel for this purchase. Required delivery date: September 25, 2026 Delivery Location: NIEHS, Rall Building 101, Laboratories E144-146, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709 The applicable NAICS code is 325413 � In-Vitro Diagnostic Substance Manufacturing. The applicable PSC is 6550 � In Vitro Diagnostic Substances, Reagents, Test Kits and Sets. Please see the attached requirements document titled �75N98026Q01226 � Requirements Document� for additional information. 2.0 UNIQUE QUALIFICATIONS OF THE CONTRACTOR The proposed contractor, Promega Corporation, is the manufacturer of the required assay reagents for the Complement-ARIE research conducted by NCATS and NIEHS. The required supplies involve specialized assay reagents designed to measure cell viability, liver injury, liver function, oxidative stress, antioxidant responses, and cellular bioenergetics in human three-dimensional microphysiological systems. The requested reagents also provide luminescence/chemiluminescence-based detection and are intended to complement established cell-painting and omics-based endpoints. The Promega assay reagents are specialized research products that are required to support the Government�s established experimental approach for evaluating toxicity-induced liver injury and associated cellular responses in human three-dimensional microphysiological systems. Due to the specific combination of required toxicological endpoints, detection technology, and compatibility with the established Complement-ARIE research methodology, use of an alternate source could require modifications to the experimental design and methodologies, affect assay sensitivity, and reduce the comparability and reproducibility of results across the research program. Accordingly, Promega Corporation is the only identified responsible source capable of providing the complete combination of assay reagents required to meet the Government�s scientific and technical requirements while maintaining the established experimental approach. BASIS FOR AWARD The Government intends to issue a firm-fixed-price purchase order to Promega Corporation. However, all timely quotations received will be considered. To be considered for award, a quotation must demonstrate that the products offered satisfy all the Government's scientific and technical requirements identified in this RFQ and the attached requirements document. Award will be made to the responsible quoter whose quotation satisfies the Government's requirements and whose price is determined fair and reasonable. RESPONSE INSTRUCTIONS The response and any other information furnished must be in writing and must contain material in sufficient detail to allow the Office of Acquisition and Logistics Management (OALM) to determine whether the respondent can fulfill the requirement. Quotations shall identify the products being offered, manufacturer and part numbers, quantities, unit and total prices, delivery schedule, and sufficient technical information to demonstrate that the products offered satisfy all of the Government's scientific and technical requirements identified in the attached requirements document. All responses must be sent via email to Contract Specialist, Jordan Neal, at Jordan.Neal@nih.gov, copying Contracting Officer, Alice Pag�n Pereira, at Alice.Pagan@nih.gov by no later than 12:00 pm Eastern Time on Monday, September 21, 2026. To be eligible for award, the contractor must be registered in System for Award Management (SAM.gov) in accordance with applicable requirements. Reference: 75N98026Q01226 on all correspondence.

Who won similar work

16 award notices on SAM.gov in the last 24 months. Matched by: Same agency (National Institutes of Health), same industry group (NAICS 3254).

WinnerAwardsValueLast
SRI INTERNATIONAL Menlo Park CA 94025 USA2– + 2 sharedJul 8, 2026
CURIA GLOBAL INC2– + 2 sharedAug 5, 2026
ALCHEM LABORATORIES CORPORATION2– + 2 sharedAug 5, 2026
BIOFIRE DEFENSE LLC1$1.7MJan 10, 2025
VECTOR BIOMED INC.1$804KDec 2, 2024
MRIGLOBAL Kansas City MO 64110 USA1– + 1 sharedMay 5, 2026
MURTY PHARMACEUTICALS, INC.1– + 1 sharedJul 8, 2026
SIA PARTNERS U.S., INC.1– + 1 sharedAug 5, 2026
SOUTHWEST RESEARCH INSTITUTE San Antonio TX 78238 USA1– + 1 sharedAug 5, 2026
KYMANOX CORP1– + 1 sharedJul 8, 2026

Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.

Latest awards

Competitive landscape

For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

  • 0 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (0 filings)
  • 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
  • No corporate PAC money from them to the overseeing committees since 2024
  • 0 foreign-agent (FARA) registrations
See who and the source records with Pro

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

  • 0 bills named on the past winners' lobbying filings
  • 0 rules from the department in the last 12 months
  • 0 executive orders naming the agency in the last 12 months
See who and the source records with Pro

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.

  • 0 of the past winners are listed companies
  • 0 insider buys and 0 insider sells at them in the last 90 days
See who and the source records with Pro

Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.

Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.